Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase II Trial of High-Dose Interleukin (IL-2) With Priming and Concomitant Sargramostim (GM-CSF) in Patients With Advanced Melanoma

NCT00616564 is registered in ClinicalTrials.gov with Mt. Sinai Medical Center, Miami as lead sponsor.

NCT NCT00616564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00616564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase II Trial of High-Dose Interleukin (IL-2) With Priming and Concomitant Sargramostim (GM-CSF) in Patients With Advanced Melanoma
Lead sponsor
Mt. Sinai Medical Center, Miami
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
September 30, 2009
Enrollment
36 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma